388 related articles for article (PubMed ID: 25792466)
41. Clinical aspects and molecular analysis of Chinese patients with Wiskott-Aldrich syndrome in Taiwan.
Lee WI; Yang CY; Jaing TH; Huang JL; Chien YH; Chang KW
Int Arch Allergy Immunol; 2008; 145(1):15-23. PubMed ID: 17703096
[TBL] [Abstract][Full Text] [Related]
42. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome.
Scaramuzza S; Biasco L; Ripamonti A; Castiello MC; Loperfido M; Draghici E; Hernandez RJ; Benedicenti F; Radrizzani M; Salomoni M; Ranzani M; Bartholomae CC; Vicenzi E; Finocchi A; Bredius R; Bosticardo M; Schmidt M; von Kalle C; Montini E; Biffi A; Roncarolo MG; Naldini L; Villa A; Aiuti A
Mol Ther; 2013 Jan; 21(1):175-84. PubMed ID: 22371846
[TBL] [Abstract][Full Text] [Related]
43. Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models.
Marangoni F; Bosticardo M; Charrier S; Draghici E; Locci M; Scaramuzza S; Panaroni C; Ponzoni M; Sanvito F; Doglioni C; Liabeuf M; Gjata B; Montus M; Siminovitch K; Aiuti A; Naldini L; Dupré L; Roncarolo MG; Galy A; Villa A
Mol Ther; 2009 Jun; 17(6):1073-82. PubMed ID: 19259069
[TBL] [Abstract][Full Text] [Related]
44. Wiskott Aldrich Syndrome: A Multi-Institutional Experience From India.
Suri D; Rikhi R; Jindal AK; Rawat A; Sudhakar M; Vignesh P; Gupta A; Kaur A; Sharma J; Ahluwalia J; Bhatia P; Khadwal A; Raj R; Uppuluri R; Desai M; Taur P; Pandrowala AA; Gowri V; Madkaikar MR; Lashkari HP; Bhattad S; Kumar H; Verma S; Imai K; Nonoyama S; Ohara O; Chan KW; Lee PP; Lau YL; Singh S
Front Immunol; 2021; 12():627651. PubMed ID: 33936041
[TBL] [Abstract][Full Text] [Related]
45. Genome editing for primary immunodeficiencies: A therapeutic perspective on Wiskott-Aldrich syndrome.
Naseem A; Steinberg Z; Cavazza A
Front Immunol; 2022; 13():966084. PubMed ID: 36059471
[TBL] [Abstract][Full Text] [Related]
46. Lentiviral vectors for the treatment of Wiskott-Aldrich syndrome.
Nienhuis AW
Gene Ther; 2005 Apr; 12(7):555-6. PubMed ID: 18360950
[No Abstract] [Full Text] [Related]
47. Hematopoietic reconstitution dynamics of mobilized- and bone marrow-derived human hematopoietic stem cells after gene therapy.
Scala S; Ferrua F; Basso-Ricci L; Dionisio F; Omrani M; Quaranta P; Jofra Hernandez R; Del Core L; Benedicenti F; Monti I; Giannelli S; Fraschetta F; Darin S; Albertazzi E; Galimberti S; Montini E; Calabria A; Cicalese MP; Aiuti A
Nat Commun; 2023 May; 14(1):3068. PubMed ID: 37244942
[TBL] [Abstract][Full Text] [Related]
48. Gene therapy for Wiskott-Aldrich Syndrome.
Bosticardo M; Ferrua F; Cavazzana M; Aiuti A
Curr Gene Ther; 2014; 14(6):413-21. PubMed ID: 25245089
[TBL] [Abstract][Full Text] [Related]
49. Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro.
Dewey RA; Avedillo Díez I; Ballmaier M; Filipovich A; Greil J; Güngör T; Happel C; Maschan A; Noyan F; Pannicke U; Schwarz K; Snapper S; Welte K; Klein C
Exp Hematol; 2006 Sep; 34(9):1161-9. PubMed ID: 16939809
[TBL] [Abstract][Full Text] [Related]
50. Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome.
Candotti F
J Clin Immunol; 2018 Jan; 38(1):13-27. PubMed ID: 29086100
[TBL] [Abstract][Full Text] [Related]
51. [Clinical features and genotype analysis of 132 patients with Wiskott-Aldrich syndrome].
Li W; Liu D; Zhang X; Ding Y; Zhao X
Zhonghua Er Ke Za Zhi; 2015 Dec; 53(12):925-30. PubMed ID: 26887548
[TBL] [Abstract][Full Text] [Related]
52. Wiskott-Aldrich Syndrome in four male siblings from a consanguineous family from Lebanon.
Mansour R; El-Orfali Y; Saber A; Noun D; Youssef N; Youssef Y; Hanna-Wakim R; Dbaibo G; Abboud M; Massaad MJ
Clin Immunol; 2020 Oct; 219():108573. PubMed ID: 32814211
[TBL] [Abstract][Full Text] [Related]
53. Haploidentical bone marrow transplantation in a pediatric patient with Wiskott-Aldrich syndrome. A case report.
Pury S; López Orozco M; Pichichero G; Sasia LV; Morell D; Álvarez MS; Basquiera AL; Mas ME; Salvucci K
Arch Argent Pediatr; 2024 Feb; 122(1):e202310061. PubMed ID: 37471507
[TBL] [Abstract][Full Text] [Related]
54. Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction.
Wada T; Jagadeesh GJ; Nelson DL; Candotti F
Hum Gene Ther; 2002 Jun; 13(9):1039-46. PubMed ID: 12067437
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation.
Capo V; Castiello MC; Fontana E; Penna S; Bosticardo M; Draghici E; Poliani LP; Sergi Sergi L; Rigoni R; Cassani B; Zanussi M; Carrera P; Uva P; Dobbs K; Sacchetti N; Notarangelo LD; van Til NP; Wagemaker G; Villa A
J Allergy Clin Immunol; 2018 Sep; 142(3):928-941.e8. PubMed ID: 29241731
[TBL] [Abstract][Full Text] [Related]
56. Wiskott-Aldrich syndrome protein-deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor.
Charrier S; Blundell M; Cédrone G; Louache F; Vainchenker W; Thrasher AJ; Galy A
Haematologica; 2013 Aug; 98(8):1300-8. PubMed ID: 23445877
[TBL] [Abstract][Full Text] [Related]
57. The genotype of the original Wiskott phenotype.
Binder V; Albert MH; Kabus M; Bertone M; Meindl A; Belohradsky BH
N Engl J Med; 2006 Oct; 355(17):1790-3. PubMed ID: 17065640
[TBL] [Abstract][Full Text] [Related]
58. When
Jin YY; Wu J; Chen TX; Chen J
Front Immunol; 2019; 10():1549. PubMed ID: 31354712
[No Abstract] [Full Text] [Related]
59. Gene Therapies for Primary Immune Deficiencies.
Kohn LA; Kohn DB
Front Immunol; 2021; 12():648951. PubMed ID: 33717203
[TBL] [Abstract][Full Text] [Related]
60. Medicine. Gene therapy that works.
Verma IM
Science; 2013 Aug; 341(6148):853-5. PubMed ID: 23970689
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]